Click here for the September issue of eNews.
News
Cambridge, UK, 01 September 2020: Mursla, a liquid biopsy company, has raised £410K from the UK Government’s Future Fund and existing investors. In addition, the organisation has secured a £40K COVID-19 grant from the Cambridgeshire Capital Grant Scheme.
The funding will enable Mursla to finalise its work on its novel exosome-based liquid biopsy platform, ExoPhenoTM, with the aim of demonstrating how the platform can detect cancer signatures in plasma from solid tumours via exosomes.
Free COVID-19 risk assessment services are being offered by Bishop Simon. Bishop Simon is a Health, Safety and Biosafety Consultancy. Our Chartered Health and Safety Consultants have served, many scientific research organisations including the Medical Research Council and PSI (CRO). If you would like to tap into or expertise to carry out your COVID-19 risk assessment, review your current COVID-19 risk assessment or inspect your COVID measures then please contact us.
AMSBIO announce a new service designed to provide high-content cytometry data on cells and tissues enabling the automated analysis of fluorescent biomarkers on living cells or long-term stored biobanked cells and tissues.
Leveraging the innovative ChipCytometry platform, AMSBIO is able to offer a complete workflow solution (products and services) for high-content cytometry on cells and tissues, from sample preparation and biobanking to biomarker analysis and data mining.
The world's focus on healthcare and leadership has never been greater. COVID-19 has led us to place higher value on our health, and question what makes a good leader, in times of crisis and in securing our future.
The Life Sciences industry is somewhat unique, in that it has the power to influence both.
For those working in it, it is a challenging industry with high expectations. To manage a growing ageing population and continuously evolving healthcare needs, the life sciences industry needs innovative, high performing, happy and healthy leaders.
Stevenage Bioscience Catalyst (SBC), a leading location for development and commercialisation of cutting-edge therapeutics, is pleased to announce that Professor Jackie Hunter is to take the role of Chair in September 2020.
ANA Therapeutics, a Silicon Valley-based biotech startup, and Quotient Sciences, a leading provider of innovative drug development and manufacturing solutions, today announced a partnership to support the manufacturing of ANA Therapeutics’ drug candidate, ANA001 (niclosamide capsules), which they are developing as a potential treatment for COVID-19. As part of the collaboration, Quotient will scale up the capsule formulation, characterize and optimize the manufacturing process and ensure continuity of drug product through clinical trials.
Cambridge, UK, 17 August 2020: Horizon Discovery Group plc (LSE: HZD) ("Horizon", "the Group" or “the Company”), a cell engineering company focused on commercialising the application of gene editing and gene modulation to accelerate scientific innovation and biopharmaceutical drug development, today announces its unaudited results for the six months ended 30 June 2020.
Group Financial Highlights
Westbury, NY – Aug. 14, 2020 – BioIVT, a leading provider of research models and services for drug and diagnostic development, today announced that it is now offering same- or next-day delivery of fresh blood and immune cell products from its seven blood donor centers, which are strategically located near biopharma hubs in the US and UK, to almost anywhere in the world.